Category: Gynecology, cervical cancer prevention, and HPV care
How to Read Pap and HPV DNA Results: ASC-US, LSIL, HSIL, and HPV-Positive with a Normal Pap — What Next
Pap reads cell shape; HPV DNA reads high-risk viral genomes — different layers.
ASCCP 2019 sends to colposcopy when immediate CIN3+ risk is about ≥4%, not from the letters alone, and not as a supplement order.
Red flags — see a gynecologist now; do not self-decode
See a gynecologist now if you have post-coital bleeding, a high-grade result, or you delayed colposcopy because of advertising — a score or sachet does not change HSIL / AGC.
- Bleeding after sex, or bleeding after menopause
- HSIL, ASC-H, AGC, CIN2/CIN3, or suspected cancer, and you have not kept the colposcopy appointment
- HPV 16 or 18 positive, then delaying colposcopy because of jar advertising
- Pregnancy plus an abnormal screening result
Pap and HPV DNA are different layers — do not read one line as cancer
Pap reads cell shape; HPV DNA reads high-risk genomes — different layers, so one line is not a cancer diagnosis.
Cytology (Pap) groups cells such as NILM, ASC-US, LSIL, ASC-H, HSIL, AGC.
hrHPV DNA reports whether high-risk viral genetic material is found, and some assays type 16/18.
Per
USPSTF
(
PMID 30140884
) and
ACOG,
ages 21–29 use cytology every 3 years; ages 30–65 may choose cytology every 3 years, or high-risk HPV alone every 5 years, or co-testing every 5 years.
CDC
and natural-history data
(PMID 20022130),
most HPV infections become undetectable within about 2 years — a positive result today is not cancer today.
Proactive health review with the Advisory team
Review your severity level and receive personalized guidance from our Advisory team.
ASCCP 2019: equal risk, equal management
Colposcopy is indicated when immediate CIN3+ risk is about ≥4% — not from the letters on the report alone.
The
ASCCP Risk-Based Management
guidelines
(
PMID 32243307
) use equal management of equal risk.
Examples: HPV-positive + NILM overall about 2.1% (often 1-year follow-up); HPV 16 + NILM about 5.3% (exceeds the colposcopy threshold); HPV 18 + NILM is a special situation because of glandular-cancer association.
These figures are a study framework, not a substitute for that patient’s risk calculator, which must include prior-round screening history.
A 3-step plan for this week (not a personal protocol)
- Read Pap + HPV together (and 16/18 if typed) and write down the appointment — do not use a sachet to overwrite the letters.
- If the result is HSIL / ASC-H / AGC / HPV 16 or 18 with NILM, keep the colposcopy visit.
- If results are normal for your age, keep the USPSTF interval: 21–29 every 3 years, or 30–65 every 5 years when using high-risk HPV or co-testing.
Result decoder table — screening vs supplement vs vaccine
| Layer | What it does | What it is not | Typical timing |
|---|---|---|---|
| Cytology (Pap) | Groups cell shape: NILM / ASC-US / LSIL / HSIL / AGC | Does not name the virus type and is not a cancer diagnosis | Ages 21–29 every 3 years per USPSTF |
| hrHPV DNA | Finds high-risk viral genomes ± types 16/18 | Does not mean the body has cancer now | Ages 30–65 every 5 years (alone or co-test) |
| HPV+ and NILM (not 16/18) | Often repeat surveillance at about 1 year; pooled immediate risk ~2.1% | Not an order to swallow a virus-clearing sachet | Per gynecologist and prior-round history |
| HPV 16/18 + NILM | Usually colposcopy (16 exceeds the 4% threshold; 18 is a special situation) | Do not wait for a jar to “clear” before colposcopy | Keep the clinician’s appointment; do not self-delay |
| ASC-US + HPV negative | Immediate CIN3+ risk is very low; usually return to routine screening | Not invasive cancer | Per the USPSTF interval for your age |
| ASC-US / LSIL + HPV positive | Often meets colposcopy criteria because immediate risk is about ≥4% | Not an order for hysterectomy | Keep the colposcopy visit |
| HSIL / ASC-H / AGC | Colposcopy ± biopsy; AGC may add endometrial assessment by age | Do not replace the procedure with a drug or food supplement | Urgent — see a gynecologist |
| HPV vaccine | Prevents types not yet acquired | Does not erase an existing Pap/HPV result | Catch-up per CDC — see the vaccine article |
| Food supplement (including PCERV) | A dietary supplement product | Not a result decoder and not a substitute for Pap / vaccine / colposcopy | Never a reason to postpone an appointment |
This table follows USPSTF 2018 and ASCCP 2019 risk examples — a gynecologist uses the full history, not a single row.
Scientific mechanism: why letters on the report are still not a diagnosis
By
Asst. Prof. Dr. Norawit Raatpiboon:
HPV is a DNA virus of cervical epithelium. Cytology captures cell shape after infection or repair.
HPV DNA captures viral genome even when cells still look NILM.
Immediate CIN3+ risk therefore comes from type, duration of persistence, and prior-round history — “equal risk, equal management.”
Food supplements have no guideline-level mechanism that erases HPV genomes.
Frequently asked questions (FAQ)
How do Pap and HPV DNA tests differ?
Pap looks at cervical cell shape. HPV DNA looks for high-risk viral genomes. They are different layers. Having the virus does not mean cells are already abnormal, and some cell changes still need the HPV result, age, and prior-round history. One line on the report is not a cancer diagnosis.
If HPV is positive but Pap is normal (NILM), do I need colposcopy right away?
Not always. Under ASCCP 2019, HPV-positive + NILM overall has about 2.1% immediate CIN3+ risk, so follow-up at about 1 year is common. HPV 16 with NILM is about 5.3%, which exceeds the 4% colposcopy threshold. HPV 18 with NILM is a special situation often sent to colposcopy because of glandular-cancer association.
Does ASC-US mean cancer?
No. ASC-US means squamous cells of undetermined significance. Read it with HPV. If HPV is negative, immediate CIN3+ risk is very low and return to routine screening is typical. If HPV is positive, colposcopy or surveillance depends on age and history.
How do LSIL and HSIL differ in layer?
LSIL reflects low-grade change, often HPV-related; many HPV-positive cases meet colposcopy criteria. HSIL / ASC-H reflect higher precancer risk. See a gynecologist for colposcopy. Do not substitute a food-supplement sachet.
How often should I screen if results are normal?
USPSTF 2018 and ACOG: ages 21–29 use cytology every 3 years. Ages 30–65 may use cytology every 3 years, or high-risk HPV alone every 5 years, or co-testing every 5 years. Average-risk screening is not recommended before age 21.
Can a food supplement or PCERV replace reading a Pap result?
No. PCERV is a food supplement. It is not a result decoder and does not replace Pap, HPV DNA, colposcopy, or HPV vaccine. Advertising that “clears the virus” does not change the letters on the report.
What is AGC, and why is it more urgent than ASC-US?
AGC is atypical glandular cells — a special situation in ASCCP. Colposcopy is usual, and endometrial assessment may be added by age. Do not wait for a sachet to “clear” before seeing a clinician.
Read next in the HPV layer
References (E-E-A-T)
- PubMed — USPSTF 2018 cervical cancer screening (PMID 30140884)
- USPSTF — Cervical cancer screening recommendation
- PubMed — ASCCP 2019 risk-based management (PMID 32243307)
- ASCCP — Management guidelines
- CDC — HPV facts
- ACOG — Cervical cancer screening FAQ
- PubMed — Natural history of cervical HPV (PMID 20022130)
Medical disclaimer
This article is general education. It is not a diagnosis, not a personal ASCCP risk calculator,
and not an order to start or stop a procedure. Pap / HPV DNA interpretation belongs with a gynecologist.
If you have red-flag symptoms or a high-grade result, seek care promptly.